Top

BMC Palliative Care

Published in:

Open Access 01-12-2020 | Research article

Nothing to lose: a grounded theory study of patients’ and healthcare professionals’ perspectives of being involved in the consent process for oncology trials with non-curative intent

Authors: Mary Murphy, Eilís McCaughan, Matthew A Carson, Monica Donovan, Richard H Wilson, Donna Fitzsimons

Published in: BMC Palliative Care | Issue 1/2020

Abstract

Background

Clinical cancer research trials may offer little or no direct clinical benefit to participants where a cure is no longer possible. As such, the decision-making and consent process for patient participation is often challenging.

Aim

To gain understanding of how patients make decisions regarding clinical trial participation, from the perspective of both the patient and healthcare professionals involved.

Methods

In-depth, face to face interviews using a grounded theory approach. This study was conducted in a regional Cancer Centre in the United Kingdom. Of the 36 interviews, 16 were conducted with patients with cancer that had non-curative intent and 18 with healthcare professionals involved in the consent process.

Results

‘Nothing to lose’ was identified as the core category that underpinned all other data within the study. This highlighted the desperation articulated by participants, who asserted trial participation was the ‘only hope in the room’. The decision regarding participation was taken within a ‘trusting relationship’ that was important to both patients and professionals. Both were united in their ‘fight against cancer’. These two categories are critical in understanding the decision-making/consent process and are supported by other themes presented in the theoretical model.

Conclusion

This study presents an important insight into the complex and ethically contentious situation of consent in clinical trials that have non-curative intent. It confirms that patients with limited options trust their doctor and frequently hold unrealistic hopes for personal benefit. It highlights a need for further research to develop a more robust and context appropriate consent process.

Rickham PP. Human experimentation. Code of ethics of the world medical association. Declaration of Helsinki. Br Med J. 1964;2(5402):177. [cited 2019 Feb 18] Available from: http://www.ncbi.nlm.nih.gov/pubmed/14150898.

Katz J. The Nuremberg Code and the Nuremberg Trial. JAMA. 1996;276(20):1662. [cited 2020 Apr 22] Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.1996.03540200048030.

Sims JM. A Brief Review of the Belmont Report. Dimens Crit Care Nurs. 2010;29(4):173–4. [cited 2020 Apr 22] Available from: https://insights.ovid.com/crossref?an=00003465-201007000-00007.

Nijhawan LP, Janodia MD, Muddukrishna BS, Bhat KM, Bairy KL, Udupa N, et al. Informed consent: Issues and challenges. J Adv Pharm Technol Res. 2013;4(3):134–40. [cited 2020 Apr 21] Available from: http://www.ncbi.nlm.nih.gov/pubmed/24083200.

Abhyankar P, Velikova G, Summers B, Bekker HL. Identifying components in consent information needed to support informed decision making about trial participation: An interview study with women managing cancer. Soc Sci Med. 2016;161:83–91. [cited 2020 Apr 21] Available from: http://www.ncbi.nlm.nih.gov/pubmed/27261532.

Dellson P, Nilsson K, Jernström H, Carlsson C. Patients’ reasoning regarding the decision to participate in clinical cancer trials: an interview study. Trials. 2018;19(1):528. [cited 2020 Apr 21] Available from: http://www.ncbi.nlm.nih.gov/pubmed/30268150.

Wall L, Farmer ZL, Webb MW, Dixon MD, Nooka A, Pentz RD. Description of the types and content of phase 1 clinical trial consent conversations in practice. Clin Trials. 2015;12(6):567–74. [cited 2020 Apr 21] Available from: http://www.ncbi.nlm.nih.gov/pubmed/26319116.

Stryker JE, Wray RJ, Emmons KM, Winer E, Demetri G. Understanding the decisions of cancer clinical trial participants to enter research studies: Factors associated with informed consent, patient satisfaction, and decisional regret. Patient Educ Couns. 2006;63(1–2):104–9. [cited 2020 Apr 21] Available from: http://www.ncbi.nlm.nih.gov/pubmed/16242898.

Garrett SB, Koenig CJ, Trupin L, Hlubocky FJ, Daugherty CK, Reinert A, et al. What advanced cancer patients with limited treatment options know about clinical research: a qualitative study. Support Care Cancer. 2017;25(10):3235–42. [cited 2020 Apr 21] Available from: http://www.ncbi.nlm.nih.gov/pubmed/28488050.

10.

Jefford M, Mileshkin L, Matthews J, Raunow H, O’Kane C, Cavicchiolo T, et al. Satisfaction with the decision to participate in cancer clinical trials is high, but understanding is a problem. Support Care Cancer. 2011;19(3):371–9. [cited 2020 Apr 21] Available from: http://www.ncbi.nlm.nih.gov/pubmed/20333413.

11.

Reeder-Hayes KE, Roberts MC, Henderson GE, Dees EC. Informed Consent and Decision Making Among Participants in Novel-Design Phase I Oncology Trials. J Oncol Pract. 2017;13(10):e863–73. [cited 2020 Apr 22] Available from: http://ascopubs.org/doi/10.1200/JOP.2017.021303.

12.

Behrendt C, Golz T, Roesler C, Bertz H, Wunsch A. What do our patients understand about their trial participation? Assessing patients’ understanding of their informed consent consultation about randomised clinical trials. J Med Ethics. 2011;37(2):74–80. [cited 2020 Apr 21] Available from: http://www.ncbi.nlm.nih.gov/pubmed/21098797.

13.

Koh HK, Brach C, Harris LM, Parchman ML. A Proposed ‘Health Literate Care Model’ Would Constitute A Systems Approach To Improving Patients’ Engagement In Care. Health Aff. 2013;32(2):357–67. [cited 2020 Apr 21] Available from: http://www.ncbi.nlm.nih.gov/pubmed/23381529.

14.

Nathe JM, Krakow EF. The Challenges of Informed Consent in High-Stakes, Randomized Oncology Trials: A Systematic Review. MDM Policy Pract. 2019;4(1). [cited 2020 Apr 21] Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440043/.

15.

Daugherty C, Ratain MJ, Grochowski E, Stocking C, Kodish E, Mick R, et al. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol. 1995;13(5):1062–72. [cited 2020 Apr 21] Available from: http://ascopubs.org/doi/10.1200/JCO.1995.13.5.1062.

16.

Hutchison C. Phase I trials in cancer patients: participants’ perceptions. Eur J Cancer Care (Engl). 1998;7(1):15–22. [cited 2020 Apr 21] Available from: http://www.ncbi.nlm.nih.gov/pubmed/9582747.

17.

Dolly SO, Kalaitzaki E, Puglisi M, Stimpson S, Hanwell J, Fandos SS, et al. A study of motivations and expectations of patients seen in phase 1 oncology clinics. Cancer. 2016;122(22):3501. [cited 2020 Apr 21] Available from: http://www.ncbi.nlm.nih.gov/pubmed/27716902.

18.

Cox AC, Fallowfield LJ, Jenkins VA. Communication and informed consent in phase 1 trials: a review of the literature. Support Care Cancer. 2006;14(4):303–9. [cited 2020 Apr 21] Available from: https://europepmc.org/article/med/16633840.

19.

Appelbaum PS, Lidz CW, Grisso T. Therapeutic misconception in clinical research: frequency and risk factors. IRB. ;26(2):1–8. [cited 2020 Apr 21] Available from: http://www.ncbi.nlm.nih.gov/pubmed/15069970.

20.

Horng S, Grady C. Misunderstanding in clinical research: distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism. IRB. ;25(1):11–6. [cited 2020 Apr 21] Available from: http://www.ncbi.nlm.nih.gov/pubmed/12833900.

21.

Jansen LA. Two concepts of therapeutic optimism. J Med Ethics. 2011;37(9):563–6. [cited 2020 Apr 21] Available from: http://www.ncbi.nlm.nih.gov/pubmed/21551464.

22.

Weinfurt KP. Discursive Versus Information-Processing Perspectives on a Bioethical Problem. Theory Psychol. 2004;14(2):191–203. [cited 2020 Apr 21] Available from: http://journals.sagepub.com/doi/10.1177/0959354304042016.

23.

Kaasa S, De Conno F. Palliative care research. Eur J Cancer. 2001;37:153–9. [cited 2020 Apr 21] Available from: https://linkinghub.elsevier.com/retrieve/pii/S095980490100260X.

24.

Krouse RS. The International Conference on Malignant Bowel Obstruction: A Meeting of the Minds to Advance Palliative Care Research. J Pain Symptom Manage. 2007;34(1):S1–6. [cited 2020 Apr 21] Available from: http://www.ncbi.nlm.nih.gov/pubmed/17544251.

25.

Brown RF, Shuk E, Leighl N, Butow P, Ostroff J, Edgerson S, et al. Enhancing decision making about participation in cancer clinical trials: development of a question prompt list. Support Care Cancer. 2011;19(8):1227–38. [cited 2020 Apr 22] Available from: http://link.springer.com/10.1007/s00520-010-0942-6.

26.

Gillies K, Cotton SC, Brehaut JC, Politi MC, Skea Z. Decision aids for people considering taking part in clinical trials. Cochrane Database Syst Rev. 2015 ;(11):CD009736. [cited 2020 Apr 21] Available from: http://www.ncbi.nlm.nih.gov/pubmed/26613337.

27.

Butow P, Brown R, Aldridge J, Juraskova I, Zoller P, Boyle F, et al. Can consultation skills training change doctors’ behaviour to increase involvement of patients in making decisions about standard treatment and clinical trials: a randomized controlled trial. Heal Expect. 2015;18(6):2570–83. [cited 2020 Apr 21] Available from: http://www.ncbi.nlm.nih.gov/pubmed/24975503.

28.

Addington-Hall J. Research sensitivities to palliative care patients. Eur J Cancer Care (Engl). 2002;11(3):220–4. [cited 2020 Apr 21] Available from: http://www.ncbi.nlm.nih.gov/pubmed/12296842.

29.

Creswell JW, Preceded by: Creswell JW. Qualitative inquiry and research design : choosing among five approaches. 3rd ed. SAGE PublicationsSage CA: Los Angeles, CA; 2012. 448 p. [cited 2020 Apr 21] Available from: https://books.google.co.uk/books/about/Qualitative_Inquiry_and_Research_Design.html?id=OJYEbDtkxq8C.

30.

Glaser BG. The grounded theory perspective. Sociology Press; 2001. 232 p. [cited 2020 Apr 21] Available from: https://books.google.co.uk/books/about/The_Grounded_Theory_Perspective.html?id=XUbZQAAACAAJ&redir_esc=y.

31.

Martin VB, Gynnild A. Grounded theory : the philosophy, method, and work of Barney Glaser: BrownWalker Press; 2011. 313 p.

32.

Charmaz K. Grounded Theory as an Emergent Method. In: Hesse-Biber SN, Leavy P, editors. Handbook of emergent methods. The Guilford Press; 2008. p. 155–170.

33.

Boeije H. A Purposeful Approach to the Constant Comparative Method in the Analysis of Qualitative Interviews. Qual Quant. 2002;36(4):391–409. [cited 2020 Apr 22] Available from: http://link.springer.com/10.1023/A:1020909529486.

34.

Charmaz K, Belgrave LL. Grounded Theory. In: The Blackwell Encyclopedia of Sociology. Oxford: Wiley; 2015. [cited 2020 Apr 22] Available from: http://doi.wiley.com/10.1002/9781405165518.wbeosg070.pub2.

35.

Hall BA. The Struggle of the Diagnosed Terminally III Person to Maintain Hope. Nurs Sci Q. 1990;3(4):177–84. [cited 2020 Apr 22] Available from: http://www.ncbi.nlm.nih.gov/pubmed/2250837.

36.

Dufault K, Martocchio BC. Symposium on compassionate care and the dying experience. Hope: its spheres and dimensions. Nurs Clin North Am. 1985;20(2):379–91. [cited 2020 Apr 22] Available from: http://www.ncbi.nlm.nih.gov/pubmed/3846980.

37.

Benkel I, Wijk H, Molander U. Challenging conversations with terminally ill patients and their loved ones: Strategies to improve giving information in palliative care. SAGE Open Med. 2014 2:205031211453245. [cited 2020 Apr 22] Available from: http://www.ncbi.nlm.nih.gov/pubmed/26770726.

38.

Miller VA, Cousino M, Leek AC, Kodish ED. Hope and persuasion by physicians during informed consent. J Clin Oncol. 2014;32(29):3229–35. [cited 2020 Apr 22] Available from: http://www.ncbi.nlm.nih.gov/pubmed/25199753.

39.

Cox K. The hopes of the dying: Examining patients’ experience of participation in early phase cancer clinical trials. NT Res. 2002;7(1):60–73. [cited 2020 Apr 22] Available from: http://journals.sagepub.com/doi/10.1177/136140960200700110.

40.

Quinn GP, Koskan A, Wells KJ, Gonzalez LE, Meade CD, Pozo CLP, et al. Cancer patients’ fears related to clinical trial participation: a qualitative study. J Cancer Educ. 2012;27(2):257–62. [cited 2020 Apr 22] Available from: http://www.ncbi.nlm.nih.gov/pubmed/22271582.

41.

Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer. N Engl J Med. 2010;363(8):733–42. [cited 2020 Apr 22] Available from: http://www.ncbi.nlm.nih.gov/pubmed/20818875.

42.

McCann SK, Campbell MK, Entwistle VA. Reasons for participating in randomised controlled trials: conditional altruism and considerations for self. Trials. 2010;11(1):31. [cited 2020 Apr 22] Available from: https://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-11-31.

43.

Miller FG, Wertheimer A. The fair transaction model of informed consent: An alternative to autonomous authorization. Kennedy Inst Ethics J. 2011;21(3):201–18. [cited 2020 Sep 14] Available from: https://pubmed.ncbi.nlm.nih.gov/22073815/.

Title: Nothing to lose: a grounded theory study of patients’ and healthcare professionals’ perspectives of being involved in the consent process for oncology trials with non-curative intent
Authors: Mary Murphy
Eilís McCaughan
Matthew A Carson
Monica Donovan
Richard H Wilson
Donna Fitzsimons
Publication date: 01-12-2020
Publisher: BioMed Central
Published in: BMC Palliative Care / Issue 1/2020
Electronic ISSN: 1472-684X
DOI: https://doi.org/10.1186/s12904-020-00661-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Nothing to lose: a grounded theory study of patients’ and healthcare professionals’ perspectives of being involved in the consent process for oncology trials with non-curative intent

Abstract

Background

Aim

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Aim

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

“Transition from children’s to adult services for adolescents/young adults with life-limiting conditions: developing realist programme theory through an international comparison”

Nursing home staff’s perspective on end-of-life care of German nursing home residents: a cross-sectional survey

Development of an international Core Outcome Set (COS) for best care for the dying person: study protocol

Predictors and trajectories of ED visits among patients receiving palliative home care services: findings from a time series analysis (2013-2017)

Blessings or burdens: an Interpretative Phenomenological Analysis (IPA) study on the motivations and their impact on end-of-life caregiving among Asian family caregivers

Disseminating research findings using a massive online open course for maximising impact and developing recommendations for practice